JP2022530866A5 - - Google Patents

Info

Publication number
JP2022530866A5
JP2022530866A5 JP2021562339A JP2021562339A JP2022530866A5 JP 2022530866 A5 JP2022530866 A5 JP 2022530866A5 JP 2021562339 A JP2021562339 A JP 2021562339A JP 2021562339 A JP2021562339 A JP 2021562339A JP 2022530866 A5 JP2022530866 A5 JP 2022530866A5
Authority
JP
Japan
Prior art keywords
cancer
heterocyclyl
pharmaceutically acceptable
cancers
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021562339A
Other languages
English (en)
Japanese (ja)
Other versions
JP7624404B2 (ja
JP2022530866A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029118 external-priority patent/WO2020219448A1/en
Publication of JP2022530866A publication Critical patent/JP2022530866A/ja
Publication of JP2022530866A5 publication Critical patent/JP2022530866A5/ja
Application granted granted Critical
Publication of JP7624404B2 publication Critical patent/JP7624404B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021562339A 2019-04-22 2020-04-21 Prc2阻害剤としてのナフチリジン誘導体 Active JP7624404B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962836840P 2019-04-22 2019-04-22
US62/836,840 2019-04-22
PCT/US2020/029118 WO2020219448A1 (en) 2019-04-22 2020-04-21 Naphthyridine derivatives as prc2 inhibitors

Publications (3)

Publication Number Publication Date
JP2022530866A JP2022530866A (ja) 2022-07-04
JP2022530866A5 true JP2022530866A5 (cg-RX-API-DMAC7.html) 2023-04-19
JP7624404B2 JP7624404B2 (ja) 2025-01-30

Family

ID=70740744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562339A Active JP7624404B2 (ja) 2019-04-22 2020-04-21 Prc2阻害剤としてのナフチリジン誘導体

Country Status (4)

Country Link
US (1) US12421228B2 (cg-RX-API-DMAC7.html)
EP (1) EP3959214A1 (cg-RX-API-DMAC7.html)
JP (1) JP7624404B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020219448A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN114269748A (zh) 2019-06-05 2022-04-01 米拉蒂医疗股份有限公司 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物
CN117062818B (zh) * 2021-03-05 2026-07-31 南京再明医药有限公司 Sos1抑制剂及其制备方法和应用
CN113861172B (zh) * 2021-09-23 2024-04-16 北京大学深圳研究生院 基于苯并五元杂环的双极性荧光材料及其制备方法与有机电致发光器件
AU2023294765A1 (en) * 2022-06-17 2024-12-12 Sundance Biosciences, Inc. Kinase modulators and methods of use thereof
IL328533A (en) * 2023-11-29 2026-07-01 Riboscience Llc Bicyclic heteroaryl derivatives of 7-AZA as inhibitors of acetylnucleotide pyrophosphatase phosphodiesterase 1

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025752A1 (es) * 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2010021381A1 (ja) 2008-08-22 2010-02-25 武田薬品工業株式会社 縮合複素環誘導体およびその用途
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
MX2012012966A (es) 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
US9730925B2 (en) 2011-09-30 2017-08-15 Glaxomithkline Llc Methods of treating cancer
CA2853501A1 (en) 2011-10-27 2013-05-02 Memorial Sloan-Kettering Cancer Center Methyltransferase inhibitors for treating cancer
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2836216B1 (en) 2012-04-13 2022-06-08 Epizyme, Inc. Combination therapy for treating cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
US9105490B2 (en) 2012-09-27 2015-08-11 Taiwan Semiconductor Manufacturing Company, Ltd. Contact structure of semiconductor device
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
BR112015008480A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc compostos de benzeno substituído
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
RU2015127822A (ru) 2012-12-13 2017-01-16 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы энхансера гомолога 2 белка zeste
CA2894216A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
CA2894222A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
PL2953941T3 (pl) 2013-02-11 2017-11-30 Constellation Pharmaceuticals, Inc. Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania
US20160031907A1 (en) 2013-03-15 2016-02-04 Epizyme, Inc. Substituted Benzene Compounds
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
HK1214815A1 (zh) 2013-04-30 2016-08-05 Glaxosmithkline Intellectual Property (No. 2) Limited Zeste增强子同源物2的抑制剂
CA2914414A1 (en) 2013-06-06 2014-12-11 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
CA2917463A1 (en) 2013-07-10 2015-01-15 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015077194A1 (en) 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
US20160361309A1 (en) 2014-02-26 2016-12-15 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
AU2015225775B2 (en) 2014-03-07 2017-06-15 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
PL3121175T3 (pl) 2014-03-17 2020-06-01 Daiichi Sankyo Company, Limited Pochodne 1,3-benzodioksolu jako inhibitory ezh1 i/lub ezh2
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
MA40848A (fr) 2014-10-28 2021-05-05 Glaxosmithkline Ip No 2 Ltd Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)
CA2964629A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
BR112017009440A2 (pt) 2014-11-06 2017-12-19 Dana Farber Cancer Inst Inc uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd)
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ezh2抑制劑
WO2016102493A1 (en) 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors
IL236420A (en) 2014-12-23 2016-06-30 Ron Schneider Methods and systems for producing an enlarged 3D image
MX375970B (es) * 2014-12-23 2025-03-06 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos.
EP3250552B1 (en) 2015-01-30 2019-03-27 Genentech, Inc. Therapeutic compounds and uses thereof
US20180037568A1 (en) 2015-02-13 2018-02-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
SI3378859T1 (sl) 2015-11-19 2020-03-31 Jiangsu Hengrui Medicine Co., Ltd., Derivat benzofurana, postopek za njegovo pripravo in njegova uporaba v medicini
EP3386513A2 (en) 2015-12-07 2018-10-17 Epizyme Inc Inhibitors of ezh2 and methods of use thereof
WO2017174023A1 (zh) 2016-04-08 2017-10-12 南京明德新药研发股份有限公司 作为ezh2抑制剂的联苯化合物
WO2017184999A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
WO2017191545A1 (en) 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
US9957274B2 (en) 2016-05-06 2018-05-01 Abbvie Inc. Indane inhibitors of EED and methods of their use
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
JP2019524872A (ja) * 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2019062435A1 (zh) 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CN109942556A (zh) 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
CN110156787B (zh) 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN114269748A (zh) 2019-06-05 2022-04-01 米拉蒂医疗股份有限公司 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物

Similar Documents

Publication Publication Date Title
JP2022535577A5 (cg-RX-API-DMAC7.html)
JP2022548255A5 (cg-RX-API-DMAC7.html)
JP2024540839A5 (cg-RX-API-DMAC7.html)
JP2025506408A5 (cg-RX-API-DMAC7.html)
JP2025000632A5 (cg-RX-API-DMAC7.html)
JP2024525993A5 (cg-RX-API-DMAC7.html)
JP2024537136A5 (cg-RX-API-DMAC7.html)
JP2022500385A5 (cg-RX-API-DMAC7.html)
JP2022500381A5 (cg-RX-API-DMAC7.html)
JP2022500388A5 (cg-RX-API-DMAC7.html)
JP2025000629A5 (cg-RX-API-DMAC7.html)
JP2022500384A5 (cg-RX-API-DMAC7.html)
IL314486A (en) Quinazoline compounds inhibit PAN-KRAS
JP2023507571A5 (cg-RX-API-DMAC7.html)
JP2019516718A5 (cg-RX-API-DMAC7.html)
JP2024537139A5 (cg-RX-API-DMAC7.html)
HRP20230377T1 (hr) Inhibitori mutacije kras g12c
JP2024537137A5 (cg-RX-API-DMAC7.html)
JP2016504289A5 (cg-RX-API-DMAC7.html)
JP2022549375A5 (cg-RX-API-DMAC7.html)
JP2021519779A5 (cg-RX-API-DMAC7.html)
FI3849537T3 (fi) Yhdistelmäterapioita
JP5271911B2 (ja) グルココルチコイド受容体リガンドとしての2−[1−フェニル−5−ヒドロキシ又はメトキシ−4α−メチル−ヘキサヒドロシクロペンタ[f]インダゾール−5−イル]エチルフェニル誘導体
JP2010540602A5 (cg-RX-API-DMAC7.html)
JP2020510664A5 (cg-RX-API-DMAC7.html)